Large B-cell lymphoma with IRF4 rearrangement: a multi-centric study with focus on potential misleading phenotypes

被引:1
|
作者
Pizzi, Marco [1 ]
Bongiovanni, Lucia [2 ]
Lorenzi, Luisa [3 ]
Righi, Simona [4 ,5 ]
Scarmozzino, Federico [1 ]
Balzarini, Piera [3 ]
Santoro, Luisa [1 ]
Mussolin, Lara [6 ]
Carraro, Elisa [6 ]
Pillon, Marta [6 ]
Bonaldi, Laura [7 ]
Vianello, Fabrizio [8 ]
Agostinelli, Claudio [4 ,5 ]
Ponzoni, Maurilio [2 ]
Tos, Angelo Paolo Dei [1 ]
Sabattini, Elena [5 ]
机构
[1] Univ Padua, Dept Med DIMED, Surg Pathol & Cytopathol Unit, Sch Med, Via A Gabelli 61, I-35121 Padua, PD, Italy
[2] Univ Vita Salute San Raffaele, San Raffaele Sci Inst, Pathol Unit, Haematopathol Diagnost Area, Milan, Italy
[3] Univ Brescia, Sch Med, Dept Mol & Translat Med, Sect Pathol,Spedali Civili Brescia, Brescia, Italy
[4] Univ Bologna, Dept Expt Diagnost & Specialty Med, Bologna, Italy
[5] Univ Bologna, Microbiol Unit, IRCCS Azienda Osped, Bologna, Italy
[6] Univ Padua, Pediat Hematol Oncol & Stem Cell Transplant Ctr, Maternal & Child Hlth Dept, Oncohematol Unit,Sch Med, Padua, Italy
[7] IRCSS Ist Oncol Veneto, Immunol & Mol Oncol Unit, Padua, Italy
[8] Univ Padua, Dept Med DIMED, Hematol & Clin Immunol Unit, Sch Med, Padua, Italy
关键词
Large B-cell lymphoma with IRF4 rearrangement; Pediatric lymphoma; Mantle cell lymphoma; SOX11; Cyclin D1; TRANSLOCATION; BCL6; CD10;
D O I
10.1007/s00428-023-03689-1
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Large B-cell lymphoma with IRF4 rearrangement (LBCL-IRF4) is a rare lymphoid neoplasm, usually occurring in the pediatric/young-adult age. Despite this, subsets of cases occur in elderly patients and express CD5, possibly entering the differential diagnosis with adult aggressive lymphomas, such as blastoid/pleomorphic mantle cell lymphoma (MCL-B/P). To better characterize the clinical-pathological features and differential diagnosis of LBCL-IRF4, we conducted a multi-centric study on 12 cases, focusing on CD5, Cyclin D1, and SOX11 expression. While most cases had typical presentation, adult-to-elderly age at diagnosis and unusual anatomic locations were reported in 3/12 (25.0%) and 2/12 (16.7%) patients, respectively. Histologically, CD5 was positive in 4/12 (33.3%) cases, Cyclin D1 was invariably negative, and SOX11 was weakly/partially expressed in 1/12 (8.3%) case. In conclusion, LBCL-IRF4 can have unconventional clinical presentations that may challenge its recognition. Although CD5 is frequently expressed, negativity for Cyclin D1 and SOX11 contributes to the differential diagnosis with MCL-B/P.
引用
收藏
页码:521 / 526
页数:6
相关论文
共 50 条
  • [41] Lenalidomide efficacy in activated B-cell-like subtype diffuse large B-cell lymphoma is dependent upon IRF4 and cereblon expression
    Zhang, Ling-Hua
    Kosek, Jolanta
    Wang, Maria
    Heise, Carla
    Schafer, Peter H.
    Chopra, Rajesh
    BRITISH JOURNAL OF HAEMATOLOGY, 2013, 160 (04) : 487 - 502
  • [42] Triple Positive (CD10+BCL6+MUM1+) Diffuse Large B-Cell Lymphomas Are a Heterogenous Group Enriched in Large B-Cell Lymphomas with IRF4 Rearrangement
    Frauenfeld, Leonie
    Castrejon, Natalia
    Streich, Sebastian
    Mayer, Annika
    Mankel, Barbara
    Steinhilber, Julia
    Ramis-Zaldivar, Joan Enric
    Salmeron-Villalobos, Julia
    Bonzheim, Irina
    Pinyol, Magda
    Salaverria, Itziar
    Fend, Falko
    Balague, Olga
    Campo, Elias
    Quintanilla-Fend, Leticia
    LABORATORY INVESTIGATION, 2020, 100 (SUPPL 1) : 1286 - 1287
  • [43] Triple Positive (CD10+BCL6+MUM1+) Diffuse Large B-Cell Lymphomas Are a Heterogenous Group Enriched in Large B-Cell Lymphomas with IRF4 Rearrangement
    Frauenfeld, Leonie
    Castrejon, Natalia
    Streich, Sebastian
    Mayer, Annika
    Mankel, Barbara
    Steinhilber, Julia
    Enric Ramis-Zaldivar, Joan
    Salmeron-Villalobos, Julia
    Bonzheim, Irina
    Pinyol, Magda
    Salaverria, Itziar
    Fend, Falko
    Balague, Olga
    Campo, Elias
    Quintanilla-Fend, Leticia
    MODERN PATHOLOGY, 2020, 33 (SUPPL 2) : 1286 - 1287
  • [44] Genetic landscape and prognostic value of IRF4 alterations in diffuse large B cell lymphoma patients
    Chen, X.
    Qin, Y.
    Xie, Z.
    Yang, J.
    Yang, S.
    Gui, L.
    Shi, Y-K.
    ANNALS OF ONCOLOGY, 2023, 34 : S1601 - S1601
  • [45] Large B-cell lymphoma with IRF4 gene rearrangements: Differences in clinicopathologic, immunophenotypic and cytogenetic features between pediatric and adult patients
    Berg, Holly E.
    Peterson, Jess F.
    Lee, Hee Eun
    McPhail, Ellen D.
    HUMAN PATHOLOGY, 2023, 131 : 108 - 115
  • [46] MHC class II loss in diffuse large B-cell lymphoma is inversely correlated with MUM1/IRF4 expression
    Wilkinson, Sarah
    Fernandez, Diane
    Chan, Wing
    Gascoyne, Randy
    Campo, Elias
    Jaffe, Elaine
    Staudt, Louis
    Delabie, Jan
    Rosenwald, Andreas
    Rimsza, Lisa
    CANCER RESEARCH, 2009, 69
  • [47] Distinct molecular profile of IRF4-rearranged large B-cell lymphoma
    Enric Ramis-Zaldivar, Joan
    Gonzalez-Farre, Blanca
    Balague, Olga
    Celis, Veronica
    Nadeu, Ferran
    Salmeron-Villalobos, Julia
    Andres, Mara
    Martin-Guerrero, Idoia
    Garrido-Pontnou, Marta
    Gaafar, Ayman
    Sunol, Mariona
    Barcena, Carmen
    Garcia-Bragado, Federico
    Andion, Maitane
    Azorin, Daniel
    Astigarraga, Itziar
    Sagaseta de Ilurdoz, Maria
    Sabado, Constantino
    Gallego, Soledad
    Verdu-Amoros, Jaime
    Fernandez-Delgado, Rafael
    Perez, Vanesa
    Tapia, Gustavo
    Mozos, Anna
    Torrent, Montserrat
    Solano-Paez, Palma
    Rivas-Delgado, Alfredo
    Dlouhy, Ivan
    Clot, Guillem
    Enjuanes, Anna
    Lopez-Guillermo, Armando
    Galera, Pallavi
    Oberley, Matthew J.
    Maguire, Alanna
    Ramsower, Colleen
    Rimsza, Lisa M.
    Quintanilla-Martinez, Leticia
    Jaffe, Elaine S.
    Campo, Elias
    Salaverria, Itziar
    BLOOD, 2020, 135 (04) : 274 - 286
  • [48] Super-enhancer analysis defines IRF4 as a target in anaplastic large cell lymphoma and rational design of IRF4 degrader molecules
    Giordano, C.
    Prutsch, N.
    Gurnhofer, E.
    Aplenc, A.
    Kenner, L.
    Look, A. T.
    Touaibia, M.
    Merkel, O.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 264 - 264
  • [49] A clinicopathological study of B-cell differentiation markers and transcription factors in classical Hodgkin's lymphoma: a potential prognostic role of MUM1/IRF4
    Valsami, Serena
    Pappa, Vassiliki
    Rontogianni, Dimitra
    Kontsioti, Frieda
    Papageorgiou, Efstathios
    Dervenoulas, John
    Karmiris, Themis
    Papageorgiou, Sotirios
    Harhalakis, Nikolaos
    Xiros, Nikolaos
    Nikiforakis, Emmanuel
    Economopoulos, Theofanis
    HAEMATOLOGICA, 2007, 92 (10) : 1343 - 1350
  • [50] Central nervous system ALK-negative anaplastic large cell lymphoma with IRF4/DUSP22 rearrangement
    Magaki, Shino
    Satyadev, Radha
    Chen, Zesheng
    Yung, Kathryn S.
    Vinters, Harry V.
    Kinney, Marsha C.
    Said, Jonathan W.
    BRAIN TUMOR PATHOLOGY, 2022, 39 (01) : 25 - 34